CXA 10

Drug Profile

CXA 10

Alternative Names: CXA-10

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator Complexa
  • Class Nitro compounds; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Inflammation mediator modulators; Signal transduction pathway modulators; Transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute kidney injury; Renal failure

Most Recent Events

  • 16 May 2016 Chemical information added
  • 12 Nov 2015 Complexa completes four phase I trials (NCT02127190, NCT02248051, NCT02460146, NCT02313064) in Acute kidney injury in USA
  • 12 Nov 2015 Complexa plans phase II trials for Focal segmental glomerulosclerosis (FSGS), Pulmonary arterial hypertension (PAH) and Sickle cell disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top